Polaryx Therapeutics (NASDAQ:PLYX) CEO Alex Keun Mo Yang Buys 88,453 Shares of Stock

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) CEO Alex Keun Mo Yang purchased 88,453 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the transaction, the chief executive officer directly owned 24,233,249 shares of the company’s stock, valued at $98,629,323.43. This represents a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Polaryx Therapeutics Stock Performance

NASDAQ PLYX opened at $3.05 on Friday. Polaryx Therapeutics, Inc. has a twelve month low of $2.07 and a twelve month high of $48.91. The company’s 50 day moving average price is $5.06.

Polaryx Therapeutics (NASDAQ:PLYX) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter.

Analysts Set New Price Targets

PLYX has been the topic of several analyst reports. Weiss Ratings initiated coverage on Polaryx Therapeutics in a report on Friday, April 24th. They issued a “sell (e-)” rating on the stock. Maxim Group initiated coverage on Polaryx Therapeutics in a report on Friday, February 27th. They issued a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $10.00.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.